ABSTRACT

Objective: To evaluate the efficacy and toxicity of paclitaxel plus carboplatin (TC)-based concurrent chemoradiotherapy (CCRT) followed by consolidation chemotherapy in the International Federation of Gynecology and Obstetrics (FIGO) stage IIIB/IVA cervical cancer patients.

Methods: We reviewed the medical records of FIGO stage IIIB/IVA cervical cancer patients (n=30) who had been intended to be treated with TC-based CCRT followed by consolidation chemotherapy (TC-CCRT-group) from April 2012–May 2016. Patients who had been treated with CCRT involving a single platinum agent (CCRT-group; n=52) or definitive radiotherapy alone (RT-group; n=74) from January 1997–September 2012 were also identified and used as historical controls. Survival was calculated using the Kaplan-Meier method and compared using the log-rank test.

Results: Of the 30 patients included in the TC-CCRT-group, 22 patients (73.3%) completed the planned TC-based CCRT. The most frequently observed acute grade 3/4 hematological toxicities were leukopenia and neutropenia, and diarrhea was the most common acute grade 3/4 non-hematological toxicity. After a median follow-up of 35 months, 9 patients (30.0%) had developed recurrent disease. The patients' estimated 3-year progression-free survival (PFS) and overall survival (OS) rates were 67.9% and 90.8%, respectively. In comparisons with historical control groups, the survival outcomes of TC-CCRT-group was significantly superior to CCRT-group in terms of OS (p=0.011) and significantly superior to RT-group in terms of both PFS (p=0.009) and OS (p<0.001).

Conclusion: TC-based CCRT followed by consolidation chemotherapy is safe and effective. A randomized controlled study needs to be conducted to further evaluate the efficacy of this multimodal approach in this patient population.

Keywords: Uterine Cervical Neoplasms; Chemoradiotherapy; Consolidation Chemotherapy; Prognosis
INTRODUCTION

It is generally accepted that the ability of radiotherapy to cure locally advanced cervical cancer is limited by the size of the tumor because the dose required to treat large tumors exceeds the toxicity limit of normal tissue [1]. As patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIIB/IVA disease usually have large tumors, efforts to maximize local control and improve the survival and quality of life of cervical cancer patients are necessary.

Based on the positive results obtained in randomized controlled studies conducted in the 1990s [2-5], concurrent cisplatin combined with pelvic radiotherapy (i.e., concurrent chemoradiotherapy, CCRT) has become the standard treatment for patients with stage IB or worse cervical cancer. However, according to a report about Radiation Therapy Oncology Group (RTOG) protocol 90-01, the 5-year survival rate of patients with stage IB-IIA cervical cancer that are treated with a combination of chemotherapy and radiotherapy is 78%, whereas that for patients with stage III-IVA disease is 59% [6]. Moreover, a meta-analysis of 18 randomized trials [7] found that the absolute survival benefit of adding concurrent chemotherapy to radiotherapy was 10% in stage IA-IIA, 7% in stage IIB, and 3% in stage III–IVA disease at 5 years. Therefore, new CCRT regimens that are more effective than conventional cisplatin-based CCRT need to be developed for patients with stage IIIB/IVA cervical cancer.

One strategy that might improve the outcomes of these patients is the concurrent use of platinum-based doublet chemotherapy and pelvic radiotherapy. A recent meta-analysis showed that the concurrent administration of platinum-based doublet chemotherapy with radiotherapy was associated with improved overall survival (OS) and progression-free survival (PFS) compared with radiotherapy and concurrent cisplatin chemotherapy in patients with cervical cancer [8].

Another possible strategy is the addition of consolidation chemotherapy after definitive CCRT. A 2008 meta-analysis of randomized controlled trials strongly suggested that the addition of consolidation chemotherapy to CCRT is beneficial [7]. Currently, the efficacy of platinum-based consolidation chemotherapy after pelvic CCRT for cervical cancer is being evaluated in phase III studies in both postoperative adjuvant radiotherapy [9] and definitive radiotherapy settings, The OUTBACK Trial [10].

Chemotherapy consisting of paclitaxel plus carboplatin (TC) has been shown to be effective in patients with advanced or recurrent cervical cancer. In a recent randomized phase III study, TC was demonstrated to be comparably effective to and less toxic than cisplatin plus paclitaxel in patients with stage IVB or recurrent cervical cancer [11]. Moreover, as both paclitaxel plus carboplatin have been shown to act as radiosensitizers [12,13], the use of TC concurrently with pelvic radiotherapy and/or as a consolidation chemotherapy might be appropriate in patients with stage IIIB/IVA cervical cancer.

We have recently reported that pelvic TC-based CCRT followed by consolidation chemotherapy in the adjuvant setting is safe and highly effective in women with surgically treated early-stage cervical cancer [14]. However, in the setting of definitive radiotherapy, although several clinical trials have been conducted [15-20], there is limited information available regarding the efficacy and toxicity of TC-based chemoradiotherapy followed by consolidation chemotherapy.
With an aim to improve the prognosis of FIGO stage IIIb/IVA cervical cancer patients, we retrospectively investigated whether pelvic TC-based chemoradiotherapy followed by consolidation chemotherapy achieves better outcomes than pelvic CCRT involving a single platinum agent or definitive radiotherapy alone.

MATERIALS AND METHODS

1. Patients and methods
Permission to proceed with the data acquisition and analysis was obtained from the institutional review board of Osaka University Hospital. A list of FIGO stage IIIb/IVA cervical cancer patients who had been treated with definitive radiotherapy from January 1997–May 2016 was generated from our institutional tumor registries. Through a chart review, patients who were intended to be treated with TC-based CCRT followed by consolidation chemotherapy (TC-CCRT-group; n=30) were identified. Of the 30 patients in TC-CCRT-group, 25 were treated in the context of our institutional phase II study, which is registered with the University Hospital Medical Information Network (UMIN, Registration No.: UMIN000017232).

2. Radiotherapy
The external beam radiotherapy (EBRT) was delivered with CT-based treatment planning, with a dose of 2 Gy per fraction, five times per week as reported previously [21]. The clinical target volume (CTV) included the gross disease, cervix, parametria, uterus, upper part of vagina, and regional lymph nodes (common, presacral, internal, and external iliacs). The initial 30–40 Gy was delivered to the whole pelvis with a 4-field box and then pelvic irradiation with a 4 cm-width of central shield being ensued reducing organ at risk exposure. Total pelvic side wall dose was 50 Gy in 25 fractions.

After adequate tumor regression, high-dose-rate intracavitary brachytherapy (HDR-ICBT) was performed once a week during the course of the EBRT with a midline block field. ICBT was administered to the patients using the microSelectron digital (HDR-V3) brachytherapy afterloader (Elekta Inc., Atlanta, GA, USA) with Fletcher-type (Fletcher-Williamson Asia Pacific) metal applicators (Elekta Inc.) comprising one curved central tandem applicator and two non-shielded ovoid applicators. A planning CT scan was obtained before the delivery of each fraction. The high-risk CTV and organs at risk were contoured on the planning CT according to the GEC-ESTRO guidelines using Oncentra® (Elekta Inc.).

The ICBT dose was prescribed at point A, which was defined as 2 cm above the cervical os marker and 2 cm perpendicular to the uterine axis along the plane of the uterus. The planned total dose of HDR-ICBT was 27.2 Gy in 4 fractions. After standard loading of source dwell positions and weighting with a fraction dose at point A in all patients, dwell times were then manually modified to maximize coverage of the high-risk CTV while reducing dose to the organs at risk. Patients in whom it was found that it was unlikely that ICBT would be able to irradiate the whole tumor volume were treated with interstitial brachytherapy (ISBT), as described previously [22]. EBRT was skipped on the days on which HDR-ICBT or HDR-ISBT was performed.

3. Chemotherapies
1) Concurrent chemotherapy
Chemotherapy consisting of paclitaxel (35 mg/m²) and carboplatin (area under the curve
[AUC]: 2.0, Calvert’s formula) was infused once a week prior to the EBRT (Fig. 1A). The doses of paclitaxel and carboplatin were chosen based on the findings of our previous phase I study of TC-based CCRT for patients with uterine cervical cancer [23]. Paclitaxel was administered as a 60-minute continuous infusion, and carboplatin was administered as a 30-minute infusion after the paclitaxel.

2) Consolidation chemotherapy
The patients were scheduled to begin consolidation chemotherapy within 3–5 weeks of the completion of the CCRT. Three cycles of paclitaxel (175 mg/m² in 3 hours) and carboplatin (AUC: 5.0, Calvert’s formula, in 30 minutes) were administered every 3–4 weeks [24].

4. Toxicity assessment
The patients were assessed for toxicities every week during treatment. Complications that occurred within 90 days of the start of the primary treatment were considered to be acute complications, and those that occurred more than 90 days after the start of treatment were considered to be late complications. The severity of acute complications was classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Late complications were graded according to the RTOG Late Radiation Morbidity Scoring Scheme [25].

Fig. 1. TC-based CCRT followed by consolidation chemotherapy. (A) Treatment schedule; (B) Kaplan-Meier estimates of PFS (all patients); and (C) Kaplan-Meier estimates of OS (all patients).
CCRT, concurrent chemoradiotherapy; EBRT, external beam radiation therapy; OS, overall survival; PFS, progression-free survival; TC, paclitaxel plus carboplatin.
5. Response evaluation
We evaluated the tumor response at one month after the completion of TC-based CCRT. The response to treatment was assessed according to the Response Evaluation Criteria in Solid Tumors. A complete response (CR) was defined as the disappearance of all target and non-target lesions and the absence of new lesions. A partial response (PR) was defined as at least a 30% reduction in the sum of the longest dimensions of the target lesions. Progressive disease (PD) was defined as a 20% increase in the sum of the longest dimensions of the target lesions or the development of new lesions. Stable disease (SD) implies that none of the above apply.

6. Follow-up
Once treatment ended, the patients were followed-up regularly by both gynecological oncologists and radiation oncologists, as reported previously [26]. When recurrence was suspected, a biopsy was taken for confirmation whenever possible. The median duration of the follow-up period was 35 months.

7. Control patients
A non-randomized group of patients with FIGO stage IIIB/IV A cervical cancer patients who had been treated with CCRT involving a single platinum agent (CCRT-group; n=52) or definitive radiotherapy alone (RT-group; n=74) from January 1997–September 2012 were also identified and used as historical controls. The clinicopathological characteristics of these patients are presented in Supplementary Table 1. Of these, 30 patients in CCRT-group and 21 patients in RT-group were included in our previous clinical studies [21,27]. At our institutions, nedaplatin is employed as a radiosensitizing agent for patients with cervical cancer [21,27-30]. In CCRT-group, weekly nedaplatin (40 mg/m^2) was administered intravenously during the course of pelvic radiotherapy. The radiotherapy administered to the control patients was same as the radiotherapy employed in patients in TC-CCRT-group.

8. Statistical analysis
The differences between the two groups with respect to categorical variables such as FIGO stage, performance status (PS), histology, pelvic nodal status, and hydronephrosis were assessed with Fisher’s exact test. Continuous variables such as age, maximum tumor diameter, and pretreatment hemoglobin level were analyzed with Student’s t test or Mann-Whitney U test. PFS and OS were calculated using the Kaplan-Meier method and compared using the log-rank test. PFS was defined as the time interval between the start of treatment and the detection of recurrence. OS was defined as the time from the start of treatment to the date of death or to the date of censoring. All statistical analyses were two-tailed, and p-values of less than 0.05 were considered statistically significant. MedCalc (MedCalc Software, Mariakerke, Belgium) was used for all analyses.

RESULTS
1. Patients
Thirty patients were treated with TC-based CCRT followed by consolidation chemotherapy between April 2012 and March 2016. All of the patients exhibited the Eastern Cooperative Oncology Group Scale of Performance Status (ECOG PS) of 0. The clinicopathological characteristics of the enrolled patients are presented in Table 1. The patients’ median age was 53 years (range: 30–68). Twenty-nine patients had FIGO stage IIIB disease and one had FIGO stage IVA disease. Twenty-four patients had tumors that displayed squamous cell carcinoma...
(SCC) histology, and 6 had tumors that exhibited non-SCC histology. Twenty-three patients had radiologic evidence of pelvic lymph node metastases. Although hydronephrosis was observed in 5 patients, none of these patients had renal dysfunction; i.e., an elevated serum creatinine or blood urea nitrogen level. Most patients had massive tumors (median tumor diameter: 60 mm, range: 40–76). The patients’ mean hemoglobin concentration before treatment was 12.1 g/dL (range: 7.2–14.7 g/dL).

### 2. Treatment outcomes

During the course of the pelvic EBRT, all of the patients received concurrent weekly carboplatin at a dose of AUC=2 and paclitaxel at a dose of 35 mg/m²/week. The median number of courses of concurrent chemotherapy administered was 5, and 22 out of 30 patients (73.3%) received more than 5 courses of concurrent chemotherapy (Table 2). The median duration of radiotherapy was 43 days (range: 41–52). After the completion of the TC-based CCRT, 21 patients (70.0%) received consolidation chemotherapy (median: 3 courses). The remaining 9 patients (30.0%) did not receive consolidation chemotherapy due to the following reasons: refusal in 6 patients and side effect associated with TC-based CCRT in 3 patients. Twenty-four patients (80.0%) achieved a CR, and 6 patients (20.0%) achieved a PR. Five out of 6 patients who achieved PR were subsequently treated with radical hysterectomy.

At the time of this analysis, 9 patients (30.0%) had developed recurrent lesions. Most of the recurrent lesions developed at extra-pelvic sites: local recurrence in 2 patients, local plus distant recurrence in 2 patients, and distant recurrence in 5 patients. Currently, 28 patients are alive (26 are alive without disease and 2 are alive with disease) after a median follow-up period of 35 months (Fig. 1B, C). The patients’ estimated 3-year PFS and OS rates were 67.9% and 90.8%, respectively.
3. Toxicities

Overall, the TC-based CCRT was well tolerated. As shown in Table 3, the most frequently observed grade 3–4 acute toxicities were hematological toxicities such as leukopenia and neutropenia. None of the patients developed thrombocytopenia. Grade 3–4 acute hematological and non-hematological toxicities were observed in 18 patients (60.0%) and 5 patients (16.7%), respectively. Grade 3–4 late toxicities occurred in 6 patients (20.0%): a vesicovaginal fistula in one patient, rectal bleeding in 3 patients, and hydronephrosis in 2 patients.

### Table 3. Grade 3–4 toxicities

| Type of toxicity | Patients with hematologic toxicities | No. of patients (%) |
|------------------|--------------------------------------|---------------------|
| Acute toxicity   | Total                                | 18 (60.0)           |
|                  | Leukopenia                           | 6                   |
|                  | Neutropenia                          | 0                   |
|                  | Leukopenia+Neutropenia               | 10                  |
|                  | Anemia                               | 0                   |
|                  | Thrombocytopenia                     | 1                   |
|                  | Febrile Neutropenia-Thrombocytopenia+Anemia | 1 | |
|                  | Total                                | 5 (16.7)            |
|                  | Nausea/vomiting                      | 0                   |
|                  | Diarrhea                             | 3                   |
|                  | Bowel obstruction                    | 0                   |
|                  | Fatigue                              | 1                   |
|                  | Lymph edema                          | 0                   |
|                  | Infection                            | 1                   |
|                  | Neuropathy                           | 0                   |

| Late toxicity    | Patients with late toxicities        | No. of patients (%) |
|------------------|--------------------------------------|---------------------|
|                  | Total                                | 6 (20.0)            |
|                  | Rectovaginal fistula                 | 0                   |
|                  | Vesicovaginal fistula                | 1                   |
|                  | Hematuria                            | 0                   |
|                  | Rectal bleeding                      | 3                   |
|                  | Bowel obstruction                    | 0                   |
|                  | Hydronephrosis                       | 2                   |
2 patients. Both vesicovaginal fistula and hydronephrosis were developed in patients who underwent radical hysterectomy for the persistent disease.

4. Comparisons with historical controls
We identified patients with stage IIIB/IVA cervical cancer who had received CCRT involving a single platinum agent (n=52) or radiotherapy alone (n=74) through a chart review and used them as historical controls (Supplementary Table 1). As shown in Fig. 2, TC-based CCRT followed by consolidation chemotherapy resulted in significantly improved survival compared with CCRT using single platinum agent (log-rank: PFS, p=0.100; OS, p=0.011) or radiotherapy alone (log-rank: PFS, p=0.009; OS, p<0.001).

DISCUSSION
In the current study, we have found that pelvic TC-based CCRT follow by consolidation chemotherapy was well tolerated and resulted in encouraging locoregional control and survival. The patients' estimated 3-year PFS and OS rates were 67.9% and 90.8%, respectively. Comparisons with historical control groups should always be treated with caution, as patients had not been randomly assigned into each group. However, although pelvic node metastasis, a strong poor prognostic factor, was more frequently observed in patients in TC-CCRT-group than in those in CCRT-group or RT-group (Supplementary Table 1), TC-based CCRT followed by consolidation chemotherapy was significantly superior to conventional CCRT involving a single platinum agent or definitive RT alone, which were previously employed at our institution (Fig. 2).

Concurrent cisplatin and pelvic radiotherapy has been the standard treatment for cervical cancer. A problem that can arise during the treatment of stage IIIB/IVA disease using cisplatin-based CCRT is hydronephrosis due to ureteral obstruction. It has previously been reported that the presence of hydronephrosis is an important indicator of a poor prognosis [31].

Fig. 2. Survival estimates according to treatment type. (A) Kaplan-Meier estimates of PFS according to treatment type (log-rank: TC-CCRT vs. RT, p=0.99; TC-CCRT vs. CCRT, p=0.100; CCRT vs. RT, p=0.180); (B) Kaplan-Meier estimates of OS according to treatment type (log-rank: TC-CCRT vs. RT, p<0.001; TC-CCRT vs. CCRT, p=0.011; CCRT vs. RT, p=0.066).
CCRT, concurrent chemoradiotherapy; OS, overall survival; PFS, progression-free survival; RT, definitive radiotherapy alone; TC, paclitaxel plus carboplatin.
precise incidence of ureteral obstruction is unknown, but it is reported to be 7% among all cases of invasive cervical cancer, and 55.8% among patients with stage III–IV disease [31]. Although the weekly administration of cisplatin during radiotherapy has been generally tolerated, its nephrotoxicity might limit its use in stage IIIb/IVA cervical cancer patients, especially those with impaired renal function due to ureteral obstruction. According to a report by Cetina et al. [32] only 67% of cervical cancer patients are able to receive the entire planned dose of weekly cisplatin (40 mg/m²) during pelvic EBRT, indicating the need for the development of less toxic regimens. A recent phase III trial demonstrated that CCRT involving cisplatin and gemcitabine followed by adjuvant cisplatin and gemcitabine is significantly superior to CCRT involving weekly cisplatin alone with regard to PFS and OS [33]. However, cisplatin/gemcitabine CCRT caused significant toxicities in other studies [34,35].

As shown in Table 4, the use of TC as radiosensitizing agents in locally advanced cervical cancer has been evaluated in several clinical trials. De Vos et al. [15] investigated the feasibility of combining weekly paclitaxel (60 mg/m²) and weekly carboplatin (AUC: 2) with

Table 4. Summary of studies of definitive concurrent chemoradiotherapy using paclitaxel-carboplatin in patients with cervical cancer

| Author        | Year | Phase | Radiotherapy  | Eligibility | No. of patients | PTX (mg/m²) | CBDCA (AUC) Schedule | Consolidation chemotherapy | Tolerability | Follow-up (median, mo) | Outcome          |
|---------------|------|-------|---------------|-------------|-----------------|-------------|----------------------|---------------------------|--------------|-------------------------|-----------------|
| de Vos et al. | 2004 | Phase I | Pelvic EBRT+ICBT | IB2-IVA     | 8               | 60          | 2 Weekly            | No                        | Tolerable     | 26                      | Recurrence rate was 12.5% |
| Rao et al.    | 2005 | Phase I | Pelvic EBRT+ICBT | IB2-IVA     | 15              | 50          | 1.5 to 3 Weekly     | No                        | MTD was PTX (50 mg/m²) +CBDCA (AUC 2.5) | 17            | Recurrence rate was 20% 2-year DFS was 80% 2-Year OS was 86% |
| Higgins et al.| 2007 | Phase II | Pelvic EBRT+ICBT | IB1-IVA     | 22              | 40          | 2 Weekly            | No                        | Tolerable     | 23                      | Recurrence rate was 31.8% 3-year PFS was 70% 3-Year OS was 65% |
| Lee et al.    | 2007 | Retrospective | Pelvic EBRT+ICBT | IB1-IVB     | 33              | 135         | 4.5 4 weekly       | No                        | Tolerable     | 27                      | Recurrence rate was 15.1% 3-year DFS was 75% 3-Year OS was 86% |
| Addeo et al.  | 2008 | Phase I | Pelvic EBRT+ICBT | IB2-IVA     | 9               | 30          | 5 and 6 Twice weekly | No                        | CBDCA (AUC6) was Tolerable | NA           | NA                      |
| Kim et al.    | 2012 | Phase II | Pelvic EBRT+ICBT | IB2-IVA     | 18              | 135         | 5 3 weekly         | Yes                       | Tolerable     | 35                      | Recurrence rate was 44.4% 3-year PFS was 51.9% 3-Year OS was 60% |
| Current study | 2016 | Retrospective | Pelvic EBRT+ICBT | IIIb-IVA    | 25              | 35          | 2 Weekly           | Yes                       | Tolerable     | 35                      | Recurrence rate was 30.0% 3-year PFS was 67.9% 3-Year OS was 90.8% |

AUC, area under the curve; CBDCA, carboplatin; DFS, disease-free survival; EBRT, external beam radiation therapy; ICBT, intracavitary brachytherapy; MTD, maximum tolerated dose; NA, not available; OS, overall survival; PFS, progression-free survival; PTX, paclitaxel.
pelvic radiation as a primary treatment for cervical cancer. However, they found that this regimen was poorly tolerated; grade 3 diarrhea occurred in half of the patients. Rao et al. [16] performed a dose escalation trial of weekly TC and concurrent pelvic radiotherapy and found that the maximum tolerable dose was 50 mg/m² for paclitaxel and an AUC of 2.5 for carboplatin. Addeo et al. [19] demonstrated in their phase I study that twice weekly paclitaxel (30 mg/m²) and carboplatin (AUC: 6) can be tolerated. The doses of concurrent paclitaxel and carboplatin employed in the current study (carboplatin: AUC: 2; paclitaxel: 35 mg/m²), which were based on the findings of our previous phase I study [23], were lower than those used in the abovementioned studies. Differences in ethnicity or body mass index between the reports might explain this. So far, including ours, two studies have evaluated the efficacy of TC-based CCRT followed by consolidation chemotherapy. Kim et al. [20] employed a 3-weekly schedule in stage IIB–IVA patients and reported 3-year PFS and OS rates of 51.9% and 60.0%, respectively. In contrast, although we included cases of more advanced disease (stage IIIIB/IVA), we achieved better oncological outcomes; i.e., 3-year PFS and OS rates of 67.9% and 90.8%, respectively. This survival difference between the two studies might indicate that the weekly administration of TC concurrently with pelvic radiotherapy is better than the use of a 3-weekly schedule in this patient population.

One concern regarding the use of more intensive CCRT involving platinum-based doublet chemotherapy is that it may cause excessive toxicity. In the current study, 22 patients (73.3%) were able to receive 5–6 courses of concurrent TC during pelvic EBRT without any treatment modification. Neutropenia was the most frequently observed grade 3/4 hematological toxicity. Although diarrhea was found to be a dose-limiting toxicity in previous phase I studies of TC-based CCRT [15,19], none of the patients in the current study developed grade 4 diarrhea, indicating the safety of this treatment regimen.

The limitations of our study need to be addressed. First, although 25 out of 30 patients were treated in the context of our institutional phase II study and the clinical data of these patients were collected prospectively, this study is the retrospective analysis. Thus, potential biases cannot be excluded: a selection bias might have been introduced by the physicians when they chose the salvage treatments. In addition, the accuracy of diagnosis of stage IIIIB/IVA disease might have been influenced by the training background of physicians. Second, this study involves a relatively small sample size and a relatively short follow-up period. Third, as the survival comparison with historical controls in the current study cover a long study period, changes in the choice of treatments for recurrent disease, the pretreatment work-up and diagnostic procedures, and improvements in radiotherapy procedures might have affected the patients’ survival. Lastly, although the current study has shown that TC-based CCRT followed by consolidation chemotherapy displays promising activity, it remains uncertain to what extent the observed survival benefit is attributable to the chemoradiotherapy phase or the consolidation chemotherapy phase. Thus, larger prospective studies, especially in the randomized setting, are necessary.

In summary, pelvic TC-based CCRT followed by consolidation chemotherapy is effective and exhibits an acceptable toxicity profile in FIGO stage IIIIB/IVA cervical cancer patients; i.e., it resulted in estimated 3-year PFS and OS rates of 67.9% and 90.8% after a median follow-up period of 35 months, respectively. This multimodal treatment might represent a new treatment strategy for FIGO stage IIIIB/IVA cervical cancer. A randomized controlled study needs to be conducted to further verify the efficacy of this approach in patients with stage IIIIB/IVA cervical cancer.
ACKNOWLEDGMENTS

The authors thank their colleagues Drs. Kiyoshi Yoshino, Tateki Tsutsui, Takuji Tomimatsu, Kenjiro Sawada, Yutaka Ueda, Eiji Kobayashi, Kae Hashimoto, Kazuya Mimura, and On Fukui for participating in this study.

SUPPLEMENTARY MATERIAL

Supplementary Table 1
Patient characteristics

Click here to view

REFERENCES

1. Kovalic JJ, Perez CA, Grigsby PW, Lockett MA. The effect of volume of disease in patients with carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1991;21:905-10.

2. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.

3. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.

4. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.

5. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.

6. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872-80.

7. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-12.

8. Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol 2014;134:166-71.

9. Clinical Trials.gov. Trial of postoperative chemoradiotherapy with or without consolidation chemotherapy for cervical cancer patients (NCT01755845) [Internet]. Bethesda, MD: Clinical Trials.gov; [cited 2015 Dec 1]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01755845.

10. Clinical Trials.gov. Cisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer (NCT01414608) [Internet]. Bethesda, MD: Clinical Trials.gov; [cited 2015 Dec 1]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01414608.
11. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:2129-35.

12. Yang LX, Douple EB, O’Hara JA, Wang HJ. Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 1995;143:309-15.

13. Tishler RB, Geard CR, Hall EI, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-7.

14. Mabuchi S, Isohashi F, Yokoi T, Takemura M, Yoshino K, Shiki Y, et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol 2016;141:240-6.

15. de Vos FY, Bos AM, Gietema JA, Pras E, Van der Zee AG, de Vries EG, et al. Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer. Anticancer Res 2004;24:345-8.

16. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 2005;96:168-72.

17. Lee MY, Wu HG, Kim K, Ha SW, Kim JS, Kim IA, et al. Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2007;104:95-9.

18. Higgins R, Bussey M, Naumann W, Hall J, Tait D, Haake M. Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer. Am J Obstet Gynecol 2007;197:205.e1-5.

19. Addeo D, Blank S, Muggia F, Formenti S. Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer--a phase I study. Anticancer Res 2008;28:3143-6.

20. Kim HS, Kim MK, Kim HJ, Han SS, Kim JW. Phase II. Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer. Cancer Res Treat 2012;44:97-103.

21. Mabuchi S, Ugaki H, Isohashi F, Yoshioka Y, Temma K, Yada-Hashimoto N, et al. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone. Gynecol Obstet Invest 2010;69:224-32.

22. Isohashi F, Yoshioka Y, Koizumi M, Konishi K, Sumida I, Takahashi Y, et al. High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma. Brachytherapy 2009;8:234-9.

23. Mabuchi S, Takahashi R, Isohashi F, Yokoi T, Ito K, Tsutui T, et al. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes. Int J Gynecol Cancer 2013;23:1279-86.

24. Hisamatsu T, Mabuchi S, Yoshino K, Fujita M, Enomoto T, Hamasaki T, et al. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer. Int J Gynecol Cancer 2012;22:623-9.

25. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.

26. Mabuchi S, Isohashi F, Maruoka S, Hisamatsu T, Takiuchi T, Yoshioka Y, et al. Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy. Arch Gynecol Obstet 2012;286:179-85.
27. Fujiiwa M, Isohashi F, Mabuchi S, Yoshioka Y, Seo Y, Suzuki O, et al. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors. J Radiat Res 2015;56:305-14.

28. Mabuchi S, Morishige K, Isohashi F, Yoshioka Y, Takeda T, Yamamoto T, et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol 2009;115:482-7.

29. Mabuchi S, Okazawa M, Isohashi F, Ohta Y, Maruoka S, Yoshioka Y, et al. Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases. Gynecol Oncol 2011;120:94-100.

30. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer 2013;23:567-75.

31. Lee SK, Jones HW 3rd. Prognostic significance of ureteral obstruction in primary cervical cancer. Int J Gynaecol Obstet 1994;44:59-65.

32. Cetina L, Rivera L, Hinojosa J, Poitevin A, Uribe J, López-Granillo C, et al. Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. BMC Womens Health 2006;6:3.

33. Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslja S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011;29:1678-85.

34. Wang CC, Chou HH, Yang LY, Lin H, Liou WS, Tseng CW, et al. A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: an Asian Gynecologic Oncology Group study. Gynecol Oncol 2015;137:462-7.

35. Rose PG, Degeest K, McMeekin S, Fusco N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007;107:274-9.